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We compared the efficacy and the safety of a carboplatin plus etoposide regimen (CE) vs split doses of cisplatin plus etoposide (SPE)
in elderly or poor-risk patients with extensive disease small-cell lung cancer (ED-SCLC). Eligibility criteria included: untreated ED-
SCLC; age X70 and performance status 0–2, or age o70 and PS 3. The CE arm received carboplatin area under the curve of five
intravenously (IV) on day 1 and etoposide 80mgm
 2 IV on days 1–3. The SPE arm received cisplatin 25mgm
 2 IV on days 1–3 and
etoposide 80mgm
 2 IV on days 1–3. Both regimens were given with granulocyte colony-stimulating factor support in a 21–28 day
cycle for four courses. A total of 220 patients were randomised. Median age was 74 years and 74% had a PS of 0 or 1. Major grade
3–4 toxicities were (%CE/%SPE): leucopenia 54/51, neutropenia 95/90, thrombocytopenia 56/16, infection 7/6. There was no
significant difference (CE/SPE) in the response rate (73/73%) and overall survival (median 10.6/9.9 mo; P¼0.54). Palliation scores
were very similar between the arms. Although the SPE regimen is still considered to be the standard treatment in elderly or poor-risk
patients with ED-SCLC, the CE regimen can be an alternative for this population considering the risk–benefit balance.
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Approximately half of patients with small-cell lung cancer (SCLC)
are older than 70 years, and the proportion of elderly SCLC
patients is continuously increasing in Japan (Morita, 2002).
However, since many investigators have arbitrarily excluded
elderly patients from clinical trials, no standard chemotherapeutic
regimen has been established for elderly patients with SCLC. The
Japan Clinical Oncology Group (JCOG) has reported that
carboplatin plus etoposide (CE) is an active and less toxic regimen
in elderly patients with SCLC (Okamoto et al, 1999). However,
other clinical trials have indicated that the combination chemo-
therapy of reduced (Souhami et al, 1997) or split doses of cisplatin
plus etoposide (SPE) (Murray et al, 1998; Westeel et al, 1998) can
be safely and effectively administered in elderly or poor-risk
patients with SCLC. Therefore, we conducted a phase III trial
comparing CE with SPE in elderly or poor-risk patients with SCLC.
Although elderly is not the same as poor-risk, many clinical trials
for the elderly have included both types of patients. Therefore, we
decided to include both elderly and poor-risk patients with SCLC
at the time of proposal for this phase III trial.
PATIENTS AND METHODS
Patient selection
Eligibility criteria included patients with histologically or cytolo-
gically confirmed SCLC who were X70 years of age and had an
Eastern Cooperative Oncology Group performance status (PS) of
0–2, or who were o70 years in age and had a PS of 3. Additional
criteria consisted of extensive disease (ED), chemotherapy-naive,
evaluable or measurable disease, expected survival X2 months,
adequate organ functions (leucocyte count X4000mm
 3, platelet
count X100000mm
 3, haemoglobin level X9.0gdl
 1, AST/ALT
p2  upper limit of normal range, total bilirubin p1.5mgdl
 1,
creatinine p1.5mgdl
 1, 24-h creatinine clearance (Ccr)
X50mlmin
 1, and PaO2 X60mmHg), no symptomatic pericardial
or pleural effusion requiring drainage, no active concomitant
malignancy, no senile dementia, and written informed consent.
Exclusion criteria included brain metastases requiring radio-
therapy, superior vena cava (SVC) syndrome requiring radio-
therapy, serious medical or psychiatric illness, or pregnancy or
lactation. Staging procedures included chest X-ray, computed
tomography (CT) scan of the chest, CT scan or magnetic resonance
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simaging (MRI) of the brain, CT scan or ultrasound of the abdomen,
isotope bone scanning, and bone marrow aspiration or biopsy.
Treatment protocol
Patients were randomised to either the CE arm or the SPE arm. The
CE regimen consisted of carboplatin area under the curve (AUC) of
five intravenously (IV) on day 1 and etoposide 80mgm
 2 IV on
days 1, 2, and 3. The SPE regimen consisted of cisplatin 25mgm
 2
IV on days 1, 2, and 3 and etoposide 80mgm
 2 IV on days 1, 2, and
3. Cycles were repeated every 3–4 weeks for up to four courses. In
our previous phase II study using the CE regimen for elderly
patients with SCLC, carboplatin AUC of 5 on day 1 and etoposide
100mgm
 2 on days 1, 2, and 3 were administered every 4 weeks
(Okamoto et al, 1999). However, because grade 3 or 4 neutropenia
occurred in 91% of the patients, in the current phase III trial we
decided to reduce the etoposide dosage to 80mgm
 2
on days 1, 2, and 3, and repeat the cycle every 3–4 weeks instead
of every 4 weeks. Twenty-four-hour Ccr was substituted for
glomerular filtration rate (GFR) in Calvert’s formula. Antiemetic
prophylaxis with 5-HT3 antagonists plus dexamethasone was used
at the treating physician’s discretion. According to the Japanese
approved guideline, prophylactic use of recombinant human
granulocyte colony-stimulating factor (G-CSF) was recommended
for daily administration after day 4 until the leucocyte (neutrophil)
count exceeded 10000 (5000)mm
 3. If the leucocyte (neutrophil)
count decreased to less than 3000 (1500)mm
 3, then G-CSF was
restarted. However, the actual use of G-CSF was left at the discretion
of the treating physician. Subsequent courses of chemotherapy were
initiated when leucocyte count X3000mm
 3; platelet count
X75000mm
 3;C r p1.5mgdl
 1; AST/ALTp2.5  upper limit of
normal range; and either PSp2 and ageX70 years, or PSp3a n d
ageo70 years were satisfied both after day 21 and two or more days
after the discontinuation of G-CSF. If the above criteria were not
satisfied by the first day of the next course, treatment was withheld
until full recovery. If more than 6 weeks passed from day 1 of the
last course, the patient was removed from protocol treatment. Dose
modifications were made based only on grade 4 haematologic
toxicities. If grade 4 leucopenia or neutropenia lasting 4 days or
more was present, or grade 4 thrombocytopenia occurred, the doses
for the next course were carboplatin AUC of 4 on day 1, cisplatin
20mgm
 2 for 3 days, and etoposide 60mgm
 2 for 3 days. If the
same haematologic toxicity was observed after dose reduction, the
patient was removed from protocol treatment. If grade 3 or 4 non-
haematologic toxicities, except for nausea/vomiting and hypona-
traemia, occurred, the patient was removed from protocol treatment
even if the toxicities improved thereafter.
Responders after four courses were not allowed to receive
further chemotherapy until progressive disease (PD) developed.
Although post-protocol treatment was left at the discretion of the
physician, crossover treatment was prohibited.
Evaluation
Tumour responses were evaluated according to World Health
Organization criteria (World Health Organization, 1979). Toxicities
were evaluated according to JCOG Toxicity Criteria (Tobinai et al,
1993), which are similar to the National Cancer Institute-Common
Toxicity Criteria (NCI-CTC ver 1) for the grading of toxicities.
Palliation score
Study-specific eight-item palliation scores were completed by
patients before treatment and 3 weeks after the third course of
chemotherapy. The attending physicians were not allowed to
complete the scores. The items consisted of cough, pain, anorexia,
shortness of breath, well-being, nausea, diarrhoea or constipation,
and sleep. The items were scored as not at all present (0), a little
(1), moderate (2), and very much (3). The sum of the total score
for all eight items was compared between the baseline and post-
treatment assessments. If the post-treatment score was below the
baseline score, the palliation score for that patient was judged as
having shown improvement.
Study design and statistics
This trial was designed as a multicentre, prospective, randomised
phase III trial. The study protocol was approved by the Clinical Trial
Review Committee of JCOG and the institutional review board of
each participating institution before the initiation of the study.
The primary endpoint was overall survival (OS). In this study, the
experimental arm was the CE arm and the control was the SPE arm.
The MST of our previous phase II trial for elderly patients with
extensive disease small-cell lung cancer (ED-SCLC) using the CE
regimen was 10.1 months. The MST of the SPE regimen for a similar
population was not available at the time of the study proposal.
Although Westeel and co-workers in 1998 and Murray and co-
workers in 1998 reported an excellent MST of SPE plus concurrent
chest radiotherapy for elderly or frail patients with limited disease
(LD)-SCLC, an MST of the SPE regimen for elderly or frail patients
with ED-SCLC was not available at that time. The only data available
on the CAV/PE regimen for elderly or poor-risk patients with SCLC
using reduced cisplatin (60mgm
 2 IV on day 1) were reported by
Souhami and co-workers in 1997 and the MST of that study was 5.9
months. Therefore, for statistical calculations in the current phase III
trial, we used the MST value of the Souhami trial for the control arm
instead of the MST of the SPE regimen. In addition, an individualised
A U C - b a s e dd o s i n gs t r a t e g yo fc a r b o p l a t i nw a se x p e c t e dt oh a v e
greater efficacy and less toxicity compared with the SPE regimen at
t h a tt i m e .T h i st r i a lw a sd e s i g n e da sas u p e r i o r i t yt r i a la n dt h e
planned sample size was 110 patients in each arm for 80% power to
detect a 0.67 hazard ratio for CE to SPE in OS at an alpha of 0.025
(one sided) (Schoenfeld and Richter, 1982). Patients were randomised
to receive either CE or SPE with a minimisation method for balancing
centre, PS (0–1 vs 2–3) and age (X70 years vs o70 years).
Survival distributions were compared by unstratified log-rank
test. Proportion of improvement in palliation score was evaluated
by Fisher’s exact test. The change in each symptom score by
treatment arm was evaluated by the Wilcoxon rank-sum test. The
relationship between the interval of each chemotherapy course and
the two regimens was evaluated by the Wilcoxon rank-sum test.
Multivariate analysis was performed using Cox’s proportional
hazards model to evaluate the importance of seven clinically
selected variables (treatment arm, PS, age, sex, lactate dehydro-
genase level, alkaline phosphatase level, and leucocyte count)
as prognostic factors. All P-values in this report are two sided,
excluding P-values for OS and progression-free survival (PFS).
The interim analysis was performed after half of the planned
number of patients had been enrolled in March 2002, with
adjustment for multiplicity by the alpha-spending function
(DeMets and Lan, 1994) with an O’Brien-Fleming type boundary.
Because the interim analysis did not meet the prespecified
stopping criteria, the study was continued and the planned accrual
of 220 patients was randomised in this trial.
RESULTS
Patient characteristics
Between August 1998 and February 2004, a total of 220 patients were
registered from 24 institutions. Baseline characteristics were well
balanced between the arms. Median age was 74 years, 92% were 70
years or older, 88% were male, and 74% had a PS of 0 or 1 (Table 1).
One patient in the CE arm was found to have LD after the
completion of protocol chemotherapy due to protocol violation, and
this patient was considered ineligible (Figure 1).
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sDelivery of treatment
Reasons for termination of treatment are listed in Figure 1, and
there were no major differences between the arms. Of the patients,
63% in the CE arm and 67% in the SPE arm completed four
courses, and 11% in the CE arm and 8% in the SPE arm did not
complete treatment because of toxicity or complications. Treat-
ment-related death (TRD) occurred in four patients; three patients
in the CE arm and one in the SPE arm. All TRDs of patients who
were X70 years old with a good pretreatment PS (all PS 1) were
associated with neutropenic infection, which occurred after the
first course of chemotherapy. Although the median interval of
chemotherapy was slightly more prolonged in the CE arm than in
the SPE arm, total delivered courses were similar between the arms
(Table 2). One patient in the SPE arm never received chemo-
therapy due to the occurrence of delirium after registration. Dose
reduction was more frequently observed in the CE arm than in the
SPE arm: 29% vs 10%, Po0.01. Course delay, G-CSF delivery and
total courses with G-CSF delivery were similar between the arms.
Toxicity and palliation score
Toxicities are listed in Table 3. Grade 3 or 4 leucopenia and
neutropenia occurred in 54 and 95% of the CE arm vs 51 and 90%
of the SPE arm, respectively. Grade 3 or 4 thrombocytopenia
occurred more frequently in the CE arm than in the SPE arm: 56 vs
16%, Po0.01. Gastrointestinal toxicities including nausea or
vomiting and diarrhoea were mild in both arms. There were few
grade 3 or 4 toxicities and no remarkable differences between the
arms. Other non-haematologic toxicities were similarly distributed
between the arms. Grade 3–4 hyponatraemia, mainly caused by
syndrome of inappropriate antidiuretic hormone (SIADH) secre-
tion, occurred in 14–16% of the patients. More importantly,
thrombocytopenia occurred more frequently in the CE arm, but
none of the patients in either arm showed grade 3 or 4 bleeding.
Only one patient in the CE arm showed grade 2 bleeding. Because
no grading of febrile neutropenia was listed in JCOG toxicity
criteria, the rate of the toxicity was not investigated in this study.
Baseline and post-treatment palliation scores were evaluated in
220/220 (100%) and 208/220 (95%) patients, respectively. We
handled missing values by imputing the worst score. Improvement
was achieved in 69 (63%) patients in the CE arm vs 61 (56%)
patients in the SPE arm, although the difference was not
statistically significant (P¼0.34). Similarly, there were no
statistical differences in the change of each symptom score
between the arms (Table 4).
Objective tumour response, PFS and OS
The objective response rate of 73% was quite similar between the
arms. Five CRs and 75 PRs were observed in each arm (Table 5).
Progression-free survival curves and OS curves are shown in
Figure 2A and B. Ninety-seven percent of the patients had
progressed or died at the time of final analysis. Progression-free
survival was quite similar between the arms (P¼0.20, one sided).
Table 1 Patient characteristics
CE (n¼110) SPE (n¼110) P-value
Age (years)
Median (range) 74 (56–86) 73.5 (55–85) 0.34
X70 years old (%) 102 (93) 100 (91) 0.81
Sex (male/female) 95/15 98/12 0.68
ECOG PS, 0–1/2/3 81/21/8 81/19/10 0.80
X5% weight loss 26 38 0.18
LN metastasis
Contralateral mediastinum 71 59 0.13
Supraclavicular 89 79 0.15
Distant metastasis
Liver 30 30 1.0
Lung 31 30 1.0
Brain 18 18 1.0
Bone 25 17 0.23
Adrenal 13 7 0.24
Bone marrow 12 12 1.0
CE, carboplatin plus etoposide; ECOG, Eastern Cooperative Oncology Group; LN,
lymph node; PS, performance status; SPE, split doses of cisplatin plus etoposide.
CE (N=110) SPE (N=110)
Randomisation (N=220)
Never received 
chemotherapy (N=1)
Analysed (N=110) Analysed (N=109)
69 (63%)
7 (6%)
12 (11%)
12 (11%)
3 (3%)
) % 4 ( 4
) % 3 ( 3
Reasons for termination 
of treatment N (%)
Reasons for termination 
of treatment N (%)
Completed with four courses 74 (67%)
NC with two courses 5 (5%) 
16 (15%) PD
Toxicity or complications 9 (8%)
Patient refusal 4 (4%)
1 (1%)
1 (1%)
Others
TRD
Completed with four courses
NC with two courses
PD
Toxicity or complications
Patient refusal
Others
TRD
Ineligible
(N=1)
Figure 1 Flow diagram of randomised phase III trial of CE vs SPE in
elderly or poor-risk patients with extensive disease SCLC.
Table 2 Compliance and drug delivery
CE (n¼110) SPE (n¼109
a) P-value
Median interval of each chemotherapy (days) (range)
1–2 27 (14–35) 23 (20–37) 0.02
b
2–3 25 (21–56) 22 (20–35) 0.07
b
3–4 27 (21–36) 24 (21–38) 0.05
b
Total delivered courses/projected courses 353/440 (80%) 360/436 (83%)
Dose reduction 32 (29%) 11 (10%) o0.01
c
Course delay 45 (41%) 40 (37%) 0.58
c
G-CSF delivery 81 (74%) 84 (77%) 0.64
c
No. of courses with G-CSF delivery/number of total courses 183/354 (52%) 203/362 (56%)
CE, carboplatin plus etoposide; G-CSF, granulocyte colony-stimulating factor; SPE, split doses of cisplatin plus etoposide.
aOne patient never received chemotherapy due to
delirium after registration.
bWilcoxon rank-sum test.
cFisher’s exact test.
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sThe MST was 5.2 months in the CE arm vs 4.7 months in the SPE
arm. OS was very similar between the arms (P¼0.54, one sided).
The MST and 1-year survival rate was 10.6 months and 41% in the
CE arm vs 9.9 months and 35% in the SPE arm.
Second-line chemotherapy
According to an ad-hoc survey (not pre-specified in the protocol),
130 (59%) patients (68 (62%) patients in the CE arm and 62 (56%)
in the SPE arm) received second-line chemotherapy after relapse
and the regimens were almost equally distributed between the
arms. The same regimen as the initial chemotherapy, platinum-
based combinations, and irinotecan regimens with or without
other agents were administered in 17 (15%), 48 (44%), and 40
(36%) patients in the CE arm vs 10 (9%), 44 (40%), and 40 (36%) in
Table 3 Toxicities (JCOG Toxicity Criteria, Worst Grade of Any Course)
CE SPE
Grade
Toxicity 1 2 3 4 3+4 (%) 1 2 3 4 3+4 (%) P-value
Haematologic
Leucopenia 5 45 46 13 (54) 8 43 49 7 (51) 0.79
Neutropenia 0 5 46 58 (95) 4 7 41 57 (90) 0.22
Anaemia 9 58 32 — (29) 20 45 27 — (25) 0.54
Thrombocytopenia 20 18 29 32 (56) 16 15 12 5 (16) o.01
Non-haematologic
Nausea/vomiting 40 24 2 — (2) 46 28 3 — (3) 0.68
Diarrhoea 8 9 1 0 (1) 11 3 1 0 (1) 1.0
Bilirubin — 31 0 0 (0) — 16 1 0 (1) 0.50
AST 47 9 3 0 (3) 30 8 6 0 (6) 0.33
ALT 40 9 2 0 (2) 38 8 4 0 (4) 0.45
Creatinine 10 2 0 0 (0) 27 3 1 0 (1) 0.50
Hyponatraemia 38 11 7 11 (16) 46 20 6 9 (14) 0.58
PaO2 39 21 7 1 (10) 44 23 2 1 (4) 0.22
Fever 15 15 0 0 (0) 21 16 0 0 (0) —
Infection 12 15 5 3 (7) 16 7 5 1 (6) 0.78
Bleeding 8 1 0 0 (0) 4 0 0 0 (0) —
Neurologic-sensory 2 1 0 — (0) 3 2 0 — (0) —
Alopaecia 67 22 — — 66 15 — —
CE, carboplatin plus etoposide; JCOG, Japan Clinical Oncology Group; PaO2, partial pressure of oxygen; SPE, split doses of cisplatin plus etoposide.
Table 4 Palliation score
CE SPE
Change from baseline Change from baseline
Symptom Mean (s.d.) Median (range) Mean (s.d.) Median (range) P
a
Cough  0.38 (1.16) 0 ( 3t o3 )  0.54 (1.06) 0 ( 3 to 3) 0.51
Pain  0.19 (1.00) 0 ( 3t o3 )  0.19 (0.96) 0 ( 3 to 3) 0.96
Anorexia  0.07 (1.16) 0 ( 3 to 3) 0.08 (1.22) 0 ( 3 to 3) 0.37
Shortness of
breath  0.05 (1.02) 0 ( 2t o3 )  0.31 (0.95) 0 ( 3 to 3) 0.12
Well-being  0.15 (1.13) 0 ( 3t o3 )  0.02 (1.14) 0 ( 3 to 3) 0.48
Nausea 0.16 (0.84) 0 ( 2 to 3) 0.26 (0.80) 0 ( 1 to 3) 0.21
Diarrhoea or
constipation 0.05 (1.07) 0 ( 3 to 3) 0.04 (0.99) 0 ( 3 to 3) 0.69
Sleep  0.15 (1.08) 0 ( 3t o3 )  0.04 (0.89) 0 ( 3 to 2) 0.10
Total  0.80 (6.04)  2(  12 to 22)  0.71 (5.35)  1(  15 to 21) 0.32
CE, carboplatin plus etoposide; s.d., standard deviation; SPE, split doses of cisplatin plus etoposide.
aWilcoxon rank-sum test.
Table 5 Therapeutic response (WHO)
CE SPE Total
CR 5 5 10
PR 75 75 150
NC 17 11 28
PD 11 16 27
NE 2 3 5
Total 110 110 220
Response rate 73% 73%
95% CI 63–81% 63–81%
CE, carboplatin plus etoposide; CI, confidence interval; CR, complete response; NC,
no change; NE, not evaluable; PD, progressive disease; PR, partial response; SPE, split
doses of cisplatin plus etoposide; WHO, World Health Organization.
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sthe SPE arm. Other chemotherapy regimens included topotecan
monotherapy, amrubicin monotherapy, or other regimens.
Subset analysis and multivariate analysis
Subset analysis was performed according to PS and age (Table 6).
There were no differences in OS between the arms in any
subset; thus, an interaction between treatment and PS is unlikely.
The survival curves of the patients X70 years of age with a PS of
0–2 are shown in Figure 2C, and the survival curves were very
similar with that of original overall populations. Even in the
multivariate analysis with seven selected baseline variables, there
was no difference in OS between the arms. High lactate
dehydrogenase level was most strongly associated with poor
prognosis (Table 7).
DISCUSSION
Until recently, there was no standard chemotherapeutic regimen
for elderly SCLC patients. Two phase III (Medical Research
Council Lung Cancer Working Party, 1996; Souhami et al, 1997)
and two randomised phase II trials (Pfeiffer et al, 1997; Ardizzoni
et al, 2005) have shown that suboptimal chemotherapies, such as
oral etoposide monotherapy or attenuated doses of combination
chemotherapy, may lead to reduced survival in elderly or poor-risk
SCLC patients when compared with standard doses of combination
chemotherapies. The CE regimen, which has acceptable toxicities
and reproducible efficacy, has been used in elderly or poor-risk
patients with SCLC worldwide, although there have been
substantial differences in toxicities and efficacy between the
reported phase II trials. Four trials demonstrated both favourable
toxicities and efficacy (Carney, 1995; Evans et al, 1995; Matsui
et al, 1998; Okamoto et al, 1999) and three showed somewhat
disappointing results because of suboptimal doses of oral etopo-
side (Larive et al, 2002), greater inclusion of patients with poor
prognostic factors (Samantas et al, 1999), and deterioration of
comorbidities as a result of chemotherapy (Quoix et al, 2001). No
phase III trial evaluating the role of the CE regimen in this
population has been reported until now.
This is the first phase III trial comparing carboplatin-based CE
and cisplatin-based SPE regimens in elderly or poor-risk patients
with ED-SCLC. In addition, this is also the largest randomised trial
specifically designed for elderly or poor-risk SCLC patients.
Although there was no significant difference in the palliation
scores, response rate, and OS between the arms, the efficacy of
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Figure 2 (A) PFS curves (n¼220). (B) OS curves (n¼220). (C)
Survival curves of the patients X70 years of age with a PS of 0–2
(n¼202).
Table 6 Subset analysis – overall survival
MST (months)
Subgroup Number of patients (%) CE SPE
PS 0–1 162 (74) 10.9 10.1
PS 2–3 58 (26) 8.3 8.1
o70 years and PS 3 18 (8) 7.1 6.9
X70 years and PS 0–2 202 (92) 10.8 10.0
CE, carboplatin plus etoposide; MST, median survival time; PS, performance status;
SPE, split doses of cisplatin plus etoposide.
Table 7 Multivariate analysis with baseline prognostic factors
Variables P-value
Hazard
ratio 95% CI
Treatment arm (CE vs. SPE) 0.99 0.99 0.75–1.33
Alkaline phosphatase level
(normal vs abnormal)
0.97 0.99 0.68–1.46
Lactate dehydrogenase level o0.001 1.69 1.23–2.26
(X 1.5 vs o  1.5)
Leucocyte count
(X10000/mm
3 vs o10000/mm
3) 0.06 1.82 0.99–3.36
Age (X75 years vs o75 years) 0.77 1.05 0.78–1.41
PS (2–3 vs 0–1) 0.41 1.15 0.82–1.61
Sex (female vs male) 0.13 0.70 0.45–1.11
CE¼carboplatin plus etoposide; SPE¼split doses of cisplatin plus etoposide;
PS¼performance status; CI¼confidence interval.
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or poor-risk patients with SCLC. Most toxicities were tolerable and
the treatment compliance was also favourable in both arms.
Approximately two-thirds of the patients received all four cycles of
treatment. The CE arm in the current trial had more pronounced
thrombocytopenia, which was considered manageable because
none of the patients in the CE arm showed grade 3 or 4 bleeding,
and the CE arm had a slightly prolonged course interval and a
slightly greater incidence of dose reduction. However, in our
opinion, these toxicities are less meaningful in clinical practice.
More importantly, the CE regimen does not require hydration and
can be given in an outpatient setting. Based on the results of this
study, many JCOG members prefer the CE regimen to the SPE
regimen and consider it to be more suitable for the control arm of
future phase III trials.
The MST of each regimen (10.6 months for CE vs 9.9 months for
SPE) was promising considering that this study included only
elderly or frail patients with ED-SCLC. However, some retro-
spective studies have shown that fit elderly patients who have
adequate organ functions, a good PS, and no comorbidity are
able to tolerate intensive chemotherapy well and show a similar
therapeutic response and survival rate as younger patients (Siu
et al, 1996; Yuen et al, 2000). In fact, in this trial the MST of fit
elderly patients X70 years of age with a PS of 0–1 was 10.9 months
for the CE arm and 10.1 months for the SPE arm. In contrast, the
MST of patients with a PS of 3 was only approximately 7 months.
Furthermore, the group of fit elderly patients comprised 74% of
the patients in this study. Therefore, the favourable survival rates
in our trial may be attributable to patient selection. In other words,
one limitation of this study is that the results of this trial cannot be
extrapolated to frail elderly with a poor PS and/or comorbid illness
because of the likelihood of greater inclusion of fit elderly patients
in this trial.
Although the total dose in both the CE and SPE arms
was slightly lower than the standard regimen, 92% of the patients
showed grade 3 or 4 neutropenia, and dose reduction and
course delay occurred frequently. However, the MST of both
regimens was comparable with that of non-elderly or non-selected
patients with ED-SCLC in historical reports (Noda et al, 2002; Niell
et al, 2005). These findings suggest that both regimens are not
suboptimal, but are near-full and effective doses for elderly or
poor-risk patients with ED-SCLC. The CE arm in the current trial
had a slightly prolonged course interval and a slightly greater
incidence of dose reduction when compared to the SPE regimen.
However, 95% of the patients showed grade 3 or 4 neutropenia and
56% showed grade 3 or 4 thrombocytopenia. Therefore, we believe
that the dose escalation of the CE regimen may be difficult in this
trial.
It remains unclear whether the elderly are able to tolerate a
single modest dose of cisplatin (60–80mgm
 2 IV) on day 1. We
feel that a fit elderly person who passes strict eligibility criteria can
receive a modest dose of cisplatin IV on day 1. However, the more
common situation is of elderly patients who have comorbidity and
a poor PS, and cannot tolerate a standard single dose of cisplatin.
Westeel et al (1998) and Murray et al (1998) reported that split
doses of cisplatin were safely and effectively administered in
elderly or frail patients with LD-SCLC. The SPE regimen appeared
to be an appropriate treatment for elderly patients with SCLC who
cannot tolerate a standard single dose of cisplatin. However, it
remains unclear whether fit elderly patients in our trial can tolerate
a standard single dose of cisplatin, and if so, it also remains
unclear whether fit elderly patients who receive a standard single
dose of cisplatin are able to achieve a more improved survival than
those who receive SPE. Unfortunately, no randomised study
comparing a single standard dose of cisplatin with SPE has been
reported in fit elderly patients with SCLC.
There are some problems with the design in this study. The
hypothesis was that carboplatin would improve survival, and
the design of the trial was a superiority design with survival
as the primary end point. However, this hypothesis was based on
two possible misconceptions. First, carboplatin could be better
dosed and might be more efficacious than cisplatin in SCLC.
Unfortunately, this hypothesis could not be sustained on the
basis of the available literatures. A number of clinical trials
have indicated that carboplatin-based combination chemotherapy
has a similar or slightly reduced efficacy compared with cisplatin-
based combination chemotherapy against various tumours (Go
and Adjei, 1999; Hotta et al, 2004). Therefore, our trial should
have been designed as a non-inferiority trial. However, if this
trial were planned as a non-inferiority trial, a total sample size
would be about 500 to 1000 patients, with equal expected survival
and a non-inferiority margin for hazard ratio ranging from 1.2 to
1.3. Second, the cisplatin dose in the control arm was an attenuated
dose. Souhami et al (1997) used reduced dose of cisplatin
(60mgm
 2 IV on day 1) and Murray et al (1998) used a single
course of a split cisplatin dose in their studies. These regimens
were completely different from the control arm in the present
study. A standard dose of cisplatin given in 3 days is the best way
of giving standard cisplatin (30mgm
 2 IV on days 1–3) with
etoposide (130mgm
 2 IV on days 1–3), according the North
Central Cancer Treatment Group (Maksmiuk et al, 1994). Had
standard SPE been used for the control arm, better survival might
have been achieved with increased toxicities. Another problem
with the design was the inclusion of patients with a PS of 3, even if
they were less than 70 years old. This made the target population
heterogeneous. The number of such patients actually recruited was
quite small, so emphasising the inappropriateness of their
inclusion. A further limitation of this study may be a long accrual
period of five-and-a-half years. Because our oncologists might
have been afraid of the risk of TRD or increased toxicities in frail
elderly with a poor PS and/or comorbid illness, more fit elderly
patients were selectively registered and consequently the accrual
rate was very slow.
In our trial, although both regimens were well-tolerated and
efficacy was promising, over 90% of the patients in both
arms showed grade 3 or 4 neutropenia, which may be justified
and acceptable for a clinical trial involving elderly or poor risk
patients with ED-SCLC, because only 6% of the patients showed
grade 3 or 4 infection and TRD occurred in only four (1.8%)
patients. Because all TRD occurred after the first course of
chemotherapy, careful monitoring and management is necessary,
particularly in the first course, if CE or SPE are administered to
elderly or frail patients. Several retrospective analyses (Findlay
et al, 1991; Radford et al, 1992) and a prospective study (Timmer-
Bonte et al, 2005) have shown that standard-dose chemotherapy
without G-CSF support causes more risk of early death and sepsis
in the older population. Moreover, the American Society of
Clinical Oncology (ASCO) guideline recommends the use of
prophylactic G-CSF in patients at higher risk for chemotherapy-
induced infection, such as those having a poor PS, older age, or
comorbid illness (Smith et al, 2006). In this trial, the prophylactic
use of G-CSF was recommended, but the actual use was left to the
discretion of the treating physician because the use of G-CSF leads
to increased drug cost. Although G-CSF was administered in only
54% of the total courses, we believe that the prophylactic use of G-
CSF with CE regimen should be recommended in a new trial or
clinical practice.
In conclusion, although the SPE regimen is still considered to be
the standard treatment for elderly or poor-risk patients with ED-
SCLC, the CE regimen can be an alternative for this population
considering the risk-benefit balance. Based on the results of our
trial, a phase III trial of the CE regimen vs amrubicin monotherapy,
supported by a pharmaceutical company, is now ongoing in elderly
patients with ED-SCLC in Japan, and a comparative trial of the CE
regimen vs carboplatin plus irinotecan regimen (Okamoto et al,
2006) is being discussed for a future trial in our group.
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